PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FINANCIAL RESULTS FOR FISCAL 2013
Pompano Beach, Florida, May 6, 2013 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the fiscal year ended March 31, 2013. Net income for the quarter ended March 31, 2013 was $4.6 million, or $0.23 diluted per share, compared to net income of $4.0 million, or $0.20 diluted per share, for the same quarter the prior year, an increase to earnings per share of 16.5%. Net income was $17.2 million, or $0.86 diluted per share, for the year ended March 31, 2013, compared to net income of $16.7 million, or $0.80 diluted per share, for the year ended March 31, 2012, an increase to earnings per share of 6.4%. Net sales for the quarter ended March 31, 2013 were $51.1 million, compared to $55.9 million for the quarter ended March 31, 2012, a decrease of 8.6%. For the year ended March 31, 2013 net sales were $227.8 million, compared to $238.3 million for the year ended March 31, 2012, a decrease of 4.4%. Online sales for the year ended March 31, 2013 were approximately 77% of all sales, compared to 75% for the prior year.
Menderes Akdag, President and CEO, commented: "We were able to increase our gross margins and decrease our operational expenses to improve our bottom line results for the quarter and fiscal year. For the quarter ended March 31, 2013 our gross profit increased 175 basis points, which can be attributed to a change in our product mix to higher margin items, including generics. For the quarter ended March 31, 2013 our operating expenses decreased by 124 basis points, mainly due to a reduction in advertising spending. Sales were negatively impacted during the quarter due to the colder than normal weather. The unavailability of Novartis brands, due to the manufacturerâ€™s suspended production, negatively impacted our sales for fiscal 2013; however recently this suspension was lifted for certain brands. Average order value was $73 for the fiscal year compared to $76 for the prior fiscal year, which was due to a change in product mix to lower priced items including generics and additional discounts given to customers. During the fiscal year, we maintained our quarterly dividend at $0.15 per share, while also paying a one-time special dividend of $1.00 in December 2012. In accordance with our share repurchase program, we repurchased approximately 397,000 shares paying approximately $3.9 million in fiscal 2013, with $10.2 million remaining as of March 31, 2013. For fiscal 2014 we are focusing on increasing our advertising spending to improve new order sales, shifting sales to higher margin items while continuing to expand our product offerings."
This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the year-end financial results. To access the call which is open to the public, dial (888) 455-1758 (toll free) or (203) 827-7025. Callers will be required to supply PETMEDS as the passcode. For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. on May 06, 2013 until May 20, 2013 at 11:59 P.M. To access the replay, call (866) 431-7950 (toll free) or (203) 369-0981 and enter passcode 5500.
Founded in 1996, PetMed Express is Americaâ€™s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.
This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Companyâ€™s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such "forward-looking" statements are set forth in Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2012. The Companyâ€™s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.
For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 954-979-5995.